These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38844794)

  • 1. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
    Li R; Shah PH; Stewart TF; Nam JK; Bivalacqua TJ; Lamm DL; Uchio EM; Geynisman DM; Jacob JM; Meeks JJ; Dickstein R; Pearce SM; Kang SH; Jung SI; Kamat AM; Burke JM; Keegan KA; Steinberg GD
    Nat Med; 2024 Jun; ():. PubMed ID: 38844794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
    Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
    Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
    Necchi A; Roumiguié M; Kamat AM; Shore ND; Boormans JL; Esen AA; Lebret T; Kandori S; Bajorin DF; Krieger LEM; Niglio SA; Uchio EM; Seo HK; de Wit R; Singer EA; Grivas P; Nishiyama H; Li H; Baranwal P; Van den Sigtenhorst-Fijlstra M; Kapadia E; Kulkarni GS
    Lancet Oncol; 2024 Jun; 25(6):720-730. PubMed ID: 38740030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
    Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
    Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
    Meghani K; Cooley LF; Choy B; Kocherginsky M; Swaminathan S; Munir SS; Svatek RS; Kuzel T; Meeks JJ
    Eur Urol; 2022 Dec; 82(6):602-610. PubMed ID: 36008193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Inman BA; Hahn NM; Stratton K; Kopp R; Sankin A; Skinner E; Pohar K; Gartrell BA; Pham S; Rishipathak D; Mariathasan S; Davarpanah N; Carter C; Steinberg GD
    Eur Urol Oncol; 2023 Jun; 6(3):313-320. PubMed ID: 36803840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Inman BA; Williams MB; Cookson MS; Chang SS; Sankin AI; O'Donnell MA; Sawutz D; Philipson R; Parker NR; Yla-Herttuala S; Rehm D; Jakobsen JS; Juul K; Dinney CPN
    J Urol; 2024 Jul; 212(1):74-86. PubMed ID: 38704840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Chamie K; Chang SS; Kramolowsky E; Gonzalgo ML; Agarwal PK; Bassett JC; Bjurlin M; Cher ML; Clark W; Cowan BE; David R; Goldfischer E; Guru K; Jalkut MW; Kaffenberger SD; Kaminetsky J; Katz AE; Koo AS; Sexton WJ; Tikhonenkov SN; Trabulsi EJ; Trainer AF; Spilman P; Huang M; Bhar P; Taha SA; Sender L; Reddy S; Soon-Shiong P
    NEJM Evid; 2023 Jan; 2(1):EVIDoa2200167. PubMed ID: 38320011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
    Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
    Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Li R; Sexton WJ; Dhillon J; Berglund A; Naidu S; Borjas G; Rose K; Kim Y; Wang X; Conejo-Garcia JR; Jain RK; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Zhang J
    Clin Cancer Res; 2023 Oct; 29(19):3875-3881. PubMed ID: 37505486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
    Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
    Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
    J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.